ZENSARTECH Q1 FY27 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,508 Cr
verified against source
Revenue YoY
8.9%
reported change
EBITDA
Pending
latest reported figure
Source
screener in enriched
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Zensar Technologies delivered Q1 FY27 revenue of $159.5 million, growing 8.9% YoY and 1.1% QoQ in constant currency, with BFSI vertical driving 8.3% sequential growth while Manufacturing, Healthcare-LS, and TMT declined 2-9%. The large $210M deal ramp contributed but was partially offset by weakness in the largest client and broader environment pressures. EBITDA margin contracted approximately 150bps sequentially due to pre-staffing and transition costs for the mega deal (~2%) and higher travel/visa/training expenses (~1.5%), partially offset by positive forex and bonus reversal. PAT margin stood at 12.2%, down 220bps YoY. The company launched ZenAI Agent Mesh and achieved 25%+ productivity uplift with 44% AI-generated code in certain engagements. Management prioritized growth and AI capability building over near-term margin expansion, guiding Q2 will be better than Q1 with margins staying similar through Q3 before recovery. $149.2 million order book represents a multi-quarter low. Key risk: sustained broad-based vertical declines outside BFSI could pressure revenue growth trajectory if mega deal ramp doesn't fully compensate.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects Q2 to be better than Q1, driven by continued mega deal ramp-up and seasonal improvement in demand environment.
- EBITDA and PAT margins expected to remain in similar range as Q1 for next 1-2 quarters as growth investment takes priority; margin recovery anticipated from Q3 FY27 onwards.
- Actively evaluating scaled acquisition targets in the $150-200M+ revenue range, with management noting favorable pricing environment and 2-3 assets under active consideration.
- Large deals ($25M+ TCV) constitute 20-30% of total pipeline, with no additional mega deals currently in the funnel but overall pipeline described as healthy.
Risks flagged
- CEO expressed reduced bullishness on Europe and Manufacturing-Consumer Services verticals, citing uncertain macroeconomic backdrop and shifting trade dynamics affecting client spending.
- Vertical decline of 3.8% QoQ attributed to FDA decision-making slowdown and adverse FDA rulings affecting biotech clients, plus consolidation at 1-2 key accounts where Zensar was 'consolidated out'.
- Gross margin declined ~300bps due to mega deal ramp; management acknowledged this is structural during transition phase and recovery is contingent on successful scaling by Q3.
- Analyst questioned whether 0.9-1.1x book-to-bill target is adequate given third consecutive year of low single-digit growth; management pointed to mega deal distortion but acknowledged need for improved funnel conversion.
Key quotes
- This is one of the largest opportunities our industry has seen and Zensar is well positioned to leverage it.
- We are not too worried about the large companies entering into this segment because their operations, their processes, their overall structure is not really designed for SMBs.
- At least for Q2 and Q3 we would expect the margins to be in the similar range as what we are seeing in Q1 because the ramp up and growth are priority and eventually once we have achieved that margins will follow from Q3 onwards.
Research modules